Africa news

ASA appeals against the controversial ruling by TAS on Semenya

As announced, the South African athletics association ASA will appeal against the decision of the International Sports Tribunal (TAS) about the appeal of athlete Caster Semenya. The South African Ministry of Sport has confirmed this.

The two-time Olympic champion in the 800 meters naturally has too high testosterone level. According to the new regulation of the athletics association IAAF, athletes who are confronted with it must take medication from now on. Semenya appealed against this but found no response at the TAS.

“We are appealing as soon as possible,” said the spokesman for Sports Minister, Vuyo Mhaga, to the French AFP news agency. The Athletics South Africa (ASA) wants to challenge two TAS judge because they were already involved in 2015 in a ruling concerning the Indian hydrogen sprint star Dutee Chand. “In addition, it has never been explained to us how the IAAF will make the new rules work. Finally, we believe that scientific information about hydrogen women has been completely left out of consideration.” The ASA would submit the appeal to a Swiss court.

The ASA previously stated that it was “greatly disappointed and shocked” about the TAS ruling. “We are in shock that a highly regarded body such as the TAS endorses this form of discrimination,” he said after the verdict.

ASA appeals against the controversial ruling by TAS on Semenya

The new IAAF rules apply to athletes active in distances from the 400 meters to the miles. The regulations were originally to enter into force on November 1, 2018, but that was postponed as long as the TAS proceedings were ongoing.

ASA appeals against the controversial ruling by TAS on Semenya

Tags

Oziga

Hi! My name is Zeal Oz from Sterkspruit, Eastern Cape, South Africa. I'm a freelance and content writer. I love music, traveling, group discussion and making friends. A graduate of the University of South Africa, with Bachelor of Education in Foundation Phase Teaching.Email: Oziga@afrinik.com

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button